micro-community-banner
 
  • Saved

2yr
Young Women With Breast Cancer: the Current Role of Precision Oncology

Young Women With Breast Cancer: the Current Role of Precision Oncology

Source : https://www.mdpi.com/2075-4426/13/11/1620

Young adults aged 40 years and younger with breast cancer represent less than 5% of all breast cancer cases, yet it is the leading cause of death among young women...

Approximately one-half of young adults with breast cancer diagnosed before 30 years have germline BRCA1, BRCA2, or TP53 mutations.

  • Saved

2yr
A Wrap Up of the 2023 San Antonio Breast Cancer Symposium

The 2023 San Antonio Breast Cancer Symposium took place from Dec. 5 to 9, 2023. The five-day conference brought together experts in medical, surgical, gynecologic, and radiation oncology as well as patient advocates to discuss the latest thinking on the biology, etiology, prevention, diagnosis, and treatment of breast cancer and premalignant breast disease.

  • Saved

2yr
San Antonio Breast Cancer Symposium Highlights

The 2023 San Antonio Breast Cancer Symposium is well underway and taking place from Dec. 5 to 9, 2023. The five-day conference, now in its 46th year, welcomes more than 10,000 researchers, health care professionals, and breast cancer advocates to learn about the latest advancements in diagnosing and treating breast cancer and premalignant breast disease.

  • Saved

2yr
Real-World Impact of Dual Anti-HER2 Antibodies on Cardiac Function in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer

Real-World Impact of Dual Anti-HER2 Antibodies on Cardiac Function in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer

Source : https://pubmed.ncbi.nlm.nih.gov/38007881/

Real-world impact of dual anti-HER2 antibodies on cardiac function in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer

Among patients with HER2-positive MBC treated with the CLEOPATRA regimen, the real-world incidence of dual anti-HER2 antibodies related LVSD was low.

  • Saved

2yr
Long-Term Outcomes of Neoadjuvant Immunotherapy Plus Chemotherapy in Patients With Early-Stage Triple-Negative Breast Cancer: an Extracted Individual Patient Data and Trial-Level Meta-Analysis

Long-Term Outcomes of Neoadjuvant Immunotherapy Plus Chemotherapy in Patients With Early-Stage Triple-Negative Breast Cancer: an Extracted Individual Patient Data and Trial-Level Meta-Analysis

Source : https://pubmed.ncbi.nlm.nih.gov/38012381/

Results show that nIO combined with chemotherapy can provide significant EFS and OS benefits, supporting its use as standard treatment for early-stage TNBC.

Results show that neoadjuvant immunotherapy combined with chemotherapy can provide significant event-free and overall survival benefits, supporting its use as standard treatment for early-stage triple-negative breast cancer.